


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound of formula (1):



wherein

the dashed line joining A and C(R^a) is present and represents a bond and A is a ~~N= atom or a -C(R^b)= group, or the dashed line is absent and A is a -N(R^b)- or -C(R^b)(R^e)- group;~~

R^a and R^b are both hydrogen ~~and R^e is a hydrogen atom or an optionally substituted C₁₋₆ alkyl, -CN, -CO₂H, -CO₂R¹, -CONH₂, -CONHR¹ or -CONR¹R² group;~~

~~R¹ and R² are each, independently, an optionally substituted alkyl group;~~

X is an ~~O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O)₂- or -NH- group;~~

Y is -C(R¹⁰)= in which R¹⁰ is -CONH₂, -CONHet¹, -CON(R¹²)Het², -CON(R¹²)Alk⁵Het² or -CO₂Alk⁶ wherein -NHet¹ is pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl, R¹² is a hydrogen atom or a straight or branched C₁₋₆ alkyl group, -Het² is cyclopentyl,

cyclohexyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl, Alk⁵ is a straight or branched C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene chain, optionally interrupted by one, two or three -O- or -S- atoms or -S(O)-, -S(O)₂- or -N(R¹²)- groups, and Alk⁶ is C₁₋₄ alkyl;

n is zero or the integer 1;

Alk¹ is an aliphatic or heteroaliphatic chain optionally substituted with one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, -OH, -CO₂H, -CO₂R⁴, -CO₂CH₃, -CON(CH₃)₃, -CONHR⁴, -CON(R⁴)₂, -COR⁴, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, -SH, -S(O)R⁴, -S(O)₂R⁴, C₁₋₆ alkylthio, NHR⁴, and -N(R⁴)₂, where R⁴ is an optionally substituted straight or branched C₁₋₆ alkyl group, and such that where two R⁴ groups are present they may be the same or different and, if attached to an N atom may be joined, together with the N atom to which they are attached, to form a heterocyclic ring, which heterocyclic ring may be optionally interrupted by a further heteroatom or heteroatom-containing group selected from -O-, -S-, -N(R⁴)-, -C(O)- or -C(S)-;

L¹ is a covalent bond or a linker atom or group, said linker atom or group being selected from -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R³)-, -N(R³)O-, -N(R³)NH-, -CON(R³)-, -OC(O)N(R³)-, -CSN(R³)-, -N(R³)CO-, -(R³)C(O)O-, -N(R³)CS-, -S(O)₂N(R³)-, -N(R³)S(O)₂-, -N(R³)CON(R³)-, -N(R³)CSN(R³)- and -N(R³)SO₂N(R³)-, where R³ is a hydrogen atom or a straight or branched alkyl group, and such that where L¹ contains two R³ groups these may be the same or different;

Cy¹ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group, said optional substituent being selected from halogen, C₁₋₆ alkyl, halo(C₁₋₆ alkyl), C₁₋₆ alkoxy, halo(C₁₋₆ alkoxy), cyano, -CO₂CH₃, -CO₂C(CH₃)₃, nitro, amino, -NHCH₃, -N(CH₃)₂, -COCH₃ and -NHCOCH₃;

L is an atom or chain -(CH₂)_pHet(CH₂)_q-;

p and q, which may be the same or different, are each zero or the integer 1;

Het is an -O- or -S- atom or a -C(R^{3a})(R^{3b})-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R^{3c})O-, -N(R^{3c})NH-, -N(R^{3c})C(R^{3a})(R^{3b})-, -CON(R^{3c})-, -OC(O)N(R^{3c})-, -CSN(R^{3c})-, -N(R^{3c})CO-, -N(R^{3c})C(O)O-, -N(R^{3c})CS-, -S(O)₂N(R^{3c})-, -N(R^{3c})S(O)₂-, -N(R^{3c})CON(R^{3d})-, -N(R^{3c})CSN(R^{3d})- or -N(R^{3c})S(O)₂N(R^{3d})- group and, when one or both of p and q is the integer 1, Het is additionally a -N(R^{3c})- group;

R^{3a} and R^{3b} are each independently a hydrogen atom, -OH, or an optionally substituted C₁₋₆ alkyl group;

R^{3c} and R^{3d} are each independently a hydrogen atom or a straight or branched alkyl group;

Ar is an optionally substituted aromatic or heteroaromatic group;
or a pharmaceutically acceptable salt thereof.

2. – 4. (cancelled)

5. (previously presented) A compound as claimed in claim 1 wherein Y is $-C(R^{10})=$ in which R^{10} is $-CN$, $-CONH_2$ or $-CO_2Alk^6$ and Alk^6 is C_{1-4} alkyl.

6. (previously presented) A compound as claimed in claim 1 wherein Cy^1 is phenyl or cyclopropyl.

7. (previously presented) A compound as claimed in claim 1 wherein Ar represents phenyl, halophenyl, dihalophenyl, $(C_{1-6}$ alkyl)phenyl, pyridinyl or $(C_{1-6}$ alkyl)pyridinyl.

8. (previously presented) A compound as claimed in claim 1 selected from
 - Ethyl 3-(benzylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 3-(*N*-benzyl-*N*-methylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 6-oxo-7-phenyl-3-[(1-phenylethyl)amino]-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 3-[(2,6-difluorobenzyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 3-benzyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 6-oxo-3-phenoxy-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;
 - Ethyl 6-oxo-7-phenyl-3-(phenylthio)-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 6-oxo-7-phenyl-3-[(pyridin-2-ylmethyl)amino]-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

3-(Benzylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile;

6-Oxo-7-phenyl-3-(phenylthio)-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxamide;
Ethyl 3-(benzoylamino)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 6-oxo-7-phenyl-3-[(phenylsulphonyl)amino]-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[(anilinoacarbonyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 6-oxo-7-phenyl-3-(2-phenylethyl)-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[hydroxy(phenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[hydroxy(6-methylpyridin-2-yl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[hydroxy(3-methylphenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

3-[Hydroxy(phenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile;

3-[Hydroxy(3-methylphenyl)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carbonitrile;

Ethyl 7-(cyclopropylmethyl)-3-[hydroxy(phenyl)methyl]-6-oxo-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-(anilinosulfonyl)-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[(3-methylphenyl)thio]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate;

Ethyl 3-[2-(4-methylphenyl)hydrazino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate; and

Ethyl 3-[(3-chlorophenyl)(hydroxy)methyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-*b*]pyridine-2-carboxylate.

9. (previously presented) A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

10. – 21. (cancelled)